Stock Scorecard
Stock Summary for Corbus Pharmaceuticals Holdings Inc (CRBP) - $10.10 as of 12/9/2025 8:26:57 PM EST
Total Score
10 out of 30
Safety Score
32 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CRBP
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CRBP
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CRBP
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CRBP
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CRBP (32 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 6 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 1 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CRBP
Financial Details for CRBP
Company Overview |
|
|---|---|
| Ticker | CRBP |
| Company Name | Corbus Pharmaceuticals Holdings Inc |
| Country | USA |
| Description | Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology firm based in Norwood, Massachusetts, focused on developing groundbreaking therapies that target the endocannabinoid system. With a robust pipeline aimed at treating unmet medical needs in autoimmunity, fibrosis, and oncology, Corbus is well-positioned to transform chronic disease management and improve patient outcomes. Its unique cannabinoid-based treatment approach presents a compelling investment opportunity for institutional investors seeking to capitalize on innovative advancements within the healthcare landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 10.10 |
| Price 4 Years Ago | 18.47 |
| Last Day Price Updated | 12/9/2025 8:26:57 PM EST |
| Last Day Volume | 296,910 |
| Average Daily Volume | 437,880 |
| 52-Week High | 20.56 |
| 52-Week Low | 4.64 |
| Last Price to 52 Week Low | 117.67% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 44.34 |
| Sector PE | 52.63 |
| 5-Year Average PE | -1.68 |
| Free Cash Flow Ratio | 6.56 |
| Industry Free Cash Flow Ratio | 14.50 |
| Sector Free Cash Flow Ratio | 28.62 |
| Current Ratio Most Recent Quarter | 6.31 |
| Total Cash Per Share | 1.54 |
| Book Value Per Share Most Recent Quarter | 7.35 |
| Price to Book Ratio | 1.95 |
| Industry Price to Book Ratio | 34.36 |
| Sector Price to Book Ratio | 33.49 |
| Price to Sales Ratio Twelve Trailing Months | 163.32 |
| Industry Price to Sales Ratio Twelve Trailing Months | 33.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.13 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 17,553,000 |
| Market Capitalization | 177,285,300 |
| Institutional Ownership | 61.15% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 9.85% |
| Reported EPS 12 Trailing Months | -5.49 |
| Reported EPS Past Year | -4.73 |
| Reported EPS Prior Year | -3.66 |
| Net Income Twelve Trailing Months | -67,512,000 |
| Net Income Past Year | -40,209,000 |
| Net Income Prior Year | -44,604,000 |
| Quarterly Revenue Growth YOY | -100.00% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 26,983,000 |
| Total Cash Past Year | 17,198,000 |
| Total Cash Prior Year | 13,724,000 |
| Net Cash Position Most Recent Quarter | 26,983,000 |
| Net Cash Position Past Year | 17,198,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 17,893,738 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 142,428,000 |
| Total Stockholder Equity Prior Year | -6,905,000 |
| Total Stockholder Equity Most Recent Quarter | 92,147,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -59,512,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -3.39 |
| Free Cash Flow Past Year | -41,794,000 |
| Free Cash Flow Prior Year | -36,100,476 |
Options |
|
| Put/Call Ratio | 0.09 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.69 |
| MACD Signal | -0.69 |
| 20-Day Bollinger Lower Band | 6.11 |
| 20-Day Bollinger Middle Band | 11.68 |
| 20-Day Bollinger Upper Band | 17.25 |
| Beta | 2.72 |
| RSI | 38.82 |
| 50-Day SMA | 9.63 |
| 150-Day SMA | 17.06 |
| 200-Day SMA | 14.67 |
System |
|
| Modified | 12/8/2025 9:19:04 PM EST |